UNASSIGNED: We report the first successful treatment of a 47-year-old man suffering from a primary immune complex-MPGN with iptacopan. So far established immunosuppressive therapies with prednisone and mycophenolate mofetil failed to control the current flare of the disease, mainly presenting with impaired kidney function and proteinuria within the nephrotic range. However, 3 months after starting the treatment with iptacopan urine protein-creatinine ratio decreased impressively to a level of 100-150 mg/mmol. Thereafter, low-level proteinuria and kidney function remained stable during follow-up. Do date, the treatment with iptacopan is continued as a monotherapy and is well tolerated.
UNASSIGNED: To the best of our knowledge, this is the first case report which suggests that iptacopan may be an interesting treatment option for primary immune complex-MPGN.
■我们报道了一名47岁的男性首次成功治疗,该男性患有伊托科潘的原发性免疫复合物-MPGN。到目前为止,使用泼尼松和霉酚酸酯建立的免疫抑制疗法未能控制当前的疾病发作,主要表现为肾功能受损和肾病范围内的蛋白尿。然而,在开始用伊塔科班治疗3个月后,尿蛋白-肌酐比率令人印象深刻地降低至100-150mg/mmol的水平。此后,低水平蛋白尿和肾功能在随访期间保持稳定.Dodate,伊塔科班作为单一疗法继续治疗,且耐受性良好.
■据我们所知,这是首例病例报告,提示伊塔科班可能是原发性免疫复合物-MPGN的一个有趣的治疗选择.